FOLLOWUS
Effect of Qingfei Mixture (清肺合剂) on pediatric mycoplasma pneumoniae pneumonia with phlegm heat obstructing Fei (Lung) syndrome
Effect of Qingfei Mixture (清肺合剂) on pediatric mycoplasma pneumoniae pneumonia with phlegm heat obstructing Fei (Lung) syndrome
- 中国结合医学杂志（英文版） 2017年23卷第9期 页码：681-688
- Affiliations：
Department of Pediatrics, Beijing Friendship Hospital, Capital Medical University,Beijing,China
- Author bio：
- Funds：Supported by Beijing Municipal Science and Technology Commission (No. Z151100003815020), the Capital Fund for the Development of Medical Science (TCM Board. No. SF-2007-III-23), and the Traditional Chinese Medicine Science and Technology Development Fund Project of Beijing (No. JJ2012-09);Conflict of Interest;The authors declare that there is no conflict of interest regarding the publication of this article.;Author Contributions;Cui H and Yang AJ conceived and designed the experiments;Yang AJ conducted the experiment and wrote the manuscript;Xi K conducted the animal experiment and Yao YQ performed the clinical observation;Ding YX and Yang LJ participated in the experimental operation and writing. All authors read and approved the final manuscript.
DOI：10.1007/s11655-017-2409-9
中图分类号：纸质出版日期：2017，
网络出版日期：2017-9-2，
Scan for full text
Yang, Aj., Xi, K., Yao, Yq. et al. Effect of Qingfei Mixture (清肺合剂) on pediatric mycoplasma pneumoniae pneumonia with phlegm heat obstructing Fei (Lung) syndrome., Chin. J. Integr. Med. 23, 681–688 (2017). https://doi.org/10.1007/s11655-017-2409-9
Ai-jun Yang, Kun Xi, Yan-qing Yao, et al. Effect of Qingfei Mixture (清肺合剂) on pediatric mycoplasma pneumoniae pneumonia with phlegm heat obstructing Fei (Lung) syndrome[J]. Chinese Journal of Integrative Medicine, 2017,23(9):681-688.
Yang, Aj., Xi, K., Yao, Yq. et al. Effect of Qingfei Mixture (清肺合剂) on pediatric mycoplasma pneumoniae pneumonia with phlegm heat obstructing Fei (Lung) syndrome., Chin. J. Integr. Med. 23, 681–688 (2017). https://doi.org/10.1007/s11655-017-2409-9 DOI：
Ai-jun Yang, Kun Xi, Yan-qing Yao, et al. Effect of Qingfei Mixture (清肺合剂) on pediatric mycoplasma pneumoniae pneumonia with phlegm heat obstructing Fei (Lung) syndrome[J]. Chinese Journal of Integrative Medicine, 2017,23(9):681-688. DOI： 10.1007/s11655-017-2409-9.
摘要
To explore the effect and mechanism of Qingfei Mixture (清肺合剂)
a Chinese medicine
in treating mycoplasma pneumonia (MP) in MP patients and rat model A total of 46 MP children with phlegm heat obstructing Fei (Lung) syndrome were randomly assigned to two groups by the method of random number table
with 23 children in each group. The control group was treated with intravenous infusion of azithromycin; the treatment group received intravenous infusion of azithromycin and oral administration of Qingfei Mixture. The treatment course was 7 days. Major symptoms and minor symptoms were observed and scored before and after treatments. A rat model of MP was also established. A total of 120 wistar rats were randomly divided into 5 groups: a normal group
infection group
Qingfei Mixture treatment group
azithromycin treatment group
and Qingfei Mixture + azithromycin treatment group. Each group contained 24 rats
from which every 6 were euthanatized 1
3
7 and 14 days after infection. MP DNA in pulmonary tissue homogenates was detected using real-time fluorescence quantitative polymerase chain reaction. Pathology was assessed after hematoxylin (HE) staining and lung tissue pathology scores were determined in pulmonary tissue. Transmission electron microscopic detection and electronic image analysis were performed on lung tissue 3 days after infection. Interleukin (IL)-17 was detected in serum using enzymelinked immunosorbent assay (ELISA) 7 days after infection. In the clinical study
both control and the treatment group showed improved results on removing symptoms of phlegm heat syndrome compared to the control group (P<0.05). In animal experiments
On the 7th day after MP infection
as detected by electron microscopy
the pulmonary capillary basement membranes of the azithromycin + Qingfei Mixture treatment group were much thinner than those of the azithromycin or Qingfei mixture treatment groups (P<0.05). The level of serum IL-17 in the azithromycin + Qingfei Mixture treatment group was lower than that in the azithromycin or Qingfei Mixture groups (P<0.01). Both Qingfei Mixture and azithromycin have therapeutic effects on mycoplasma pneumoniae pneumonia
but the combination of both agents had the greatest effect.
Abstract
To explore the effect and mechanism of Qingfei Mixture (清肺合剂)
a Chinese medicine
in treating mycoplasma pneumonia (MP) in MP patients and rat model A total of 46 MP children with phlegm heat obstructing Fei (Lung) syndrome were randomly assigned to two groups by the method of random number table
with 23 children in each group. The control group was treated with intravenous infusion of azithromycin; the treatment group received intravenous infusion of azithromycin and oral administration of Qingfei Mixture. The treatment course was 7 days. Major symptoms and minor symptoms were observed and scored before and after treatments. A rat model of MP was also established. A total of 120 wistar rats were randomly divided into 5 groups: a normal group
infection group
Qingfei Mixture treatment group
azithromycin treatment group
and Qingfei Mixture + azithromycin treatment group. Each group contained 24 rats
from which every 6 were euthanatized 1
3
7 and 14 days after infection. MP DNA in pulmonary tissue homogenates was detected using real-time fluorescence quantitative polymerase chain reaction. Pathology was assessed after hematoxylin (HE) staining and lung tissue pathology scores were determined in pulmonary tissue. Transmission electron microscopic detection and electronic image analysis were performed on lung tissue 3 days after infection. Interleukin (IL)-17 was detected in serum using enzymelinked immunosorbent assay (ELISA) 7 days after infection. In the clinical study
both control and the treatment group showed improved results on removing symptoms of phlegm heat syndrome compared to the control group (P<0.05). In animal experiments
On the 7th day after MP infection
as detected by electron microscopy
the pulmonary capillary basement membranes of the azithromycin + Qingfei Mixture treatment group were much thinner than those of the azithromycin or Qingfei mixture treatment groups (P<0.05). The level of serum IL-17 in the azithromycin + Qingfei Mixture treatment group was lower than that in the azithromycin or Qingfei Mixture groups (P<0.01). Both Qingfei Mixture and azithromycin have therapeutic effects on mycoplasma pneumoniae pneumonia
but the combination of both agents had the greatest effect.
关键词
mycoplasma pneumoniaepneumoniaazithromycinQingfei MixturechildrenChinese Medicine
Keywords
mycoplasma pneumoniaepneumoniaazithromycinQingfei MixturechildrenChinese Medicine
references
Gao RL, Wu YX, Deng L, Fang L. A clinical analysis of 560 cases of mycoplasma pneumoniae infection in respiratory tract infections of children. Chin J Woman Child Health Res (Chin) 2010;21:814–816.
Zhao SY, Ma Y, Zhang GF, Jiang ZF. Clinical analysis of 11 cases of severe mycoplasma pneumonia. Chin J Pract Pediatr (Chin) 2003;18:414–416.
Mao CF, Chen Y. Clinical analysis of 20 cases of children with severe pneumonia mycoplasma pneumonia. Zhejiang Med J (Chin) 2011;33:1681–1683.
Tong XP, Cai Y, Wang WL, Huang Y. Analysis of TCM syndromes of adult mycoplasma pneumoniae pneumonia and its relationship with inflammation index. Guangdong Med J (Chin) 2014;35:291–292.
Yao YQ, Cui H. Research progress of traditional chinese medicine in the treatment of children with mycoplasma pneumonia. Chin J Integr Tradit West Med (Chin) 2011;31:1436–1440.
Jiang ZF, Shen KL, Shen Y, Zhu FT, eds. Practice of pediatrics. 8th ed. Beijing: People's Medical Publishing House; 2015:1280.
Wang SC, ed. Pediatrics of Chinese medicine. Beijing: Chinese Medicine Publishing House of China; 2012:104.
Zheng XY, ed. Clinical guideline of new drugs for traditional Chinese medicine (trial). Beijing: Medical Science and Technology Press of China; 1993:224.
State Administration of Traditional Chinese Medicine. Chinese medicine industry standard of the People's Republic of China–curative effect standard of TCM syndrome diagnosis. Nanjing: Nanjing University Press; 1994:78.
Liu XH, Xin DL, Hou AC, Wei TL, Ye HC, Li J, et al. Establishment of mice models of mycoplasma pneumoniae pneumonia and the application of histopathological scoring method. Chongqing Med J (Chin) 2004;33:1338–1340.
Chen ZM. Recognition of mycoplasma pneumoniae pneumonia-a study of the pathogenesis and clinical treatment. Chin J Pract Pediatr (Chin) 2012;27:253–257.
Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K. Macrolides: from in vitro antiinflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 2012;68:479–503.
Euba B, Moleres J, Viadas C, Barberán M, Caballero L, Grilló MJ, et al. Relationship between azithromycin susceptibility and administration efficacy for nontypeable haemophilus influenzae respiratory infection. Antimicrob Agents Chemother 2015;59:2700–2712.
Wan YF, Huang ZH, Jing K, Li J, Wang Y, Xu CQ, et al. Azithromycin attenuates pulmonary inflammation and emphysema in smoking-induced COPD model in rats. Respir Care 2015;60:128–134.
Rosborough BR, Hackstein H, Turnquist HR. A Window into immunosuppressant immunoregulation: recipient conversion to rapamycin increases potentially tolerogenic immune cells. Kidney Int 2014;85:743–745.
Iwanaga N, Nakamura S, Oshima K, Kajihara T, Takazono T, Miyazaki T, et al. Macrolides promote CCl2-mediated macrophage recruitment and clearance of nasopharyngeal pneumococcal colonization in mice. J Infect Dis 2015;212:1150–1159.
Levitsky J, Mathew JM, Abecassis M, Tambur A, Leventhal J, Chandrasekaran D, et al. Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology 2013;57:239–248.
Yao YQ, Wang ZW, Ding YX, Yu Y, Jiang WX, Cui H, et al. Effect of the combination of Zhifei Mixture and Western medicine on the symptoms and signs of mycoplasma pneumoniae pneumonia. Chin J Integr Tradit West Med (Chin) 2014;34:522–525.
Yao FL, Chang FY, Yu YB. Mycoplasma pneumoniae resistance and advances in traditional Chinese medicine. Int J Pediatr (Chin) 2011;38:191–195.
Shah SS, Test M, Sheffler-Collins S, Weiss AK, Hall M. Macrolide therapy and outcomes in a multicenter cohort of children hospitalized with mycoplasma pneumoniae pneumonia. J Hosp Med 2012;7:311–317.
Kannan TR, Coalson JJ, Cagle M, Musatovova O, Hardy RD, Baseman JB. Synthesis and distribution of CARDS toxin during mycoplasma pneumoniae infection in a murine Model. J Infect Dis 2011;204:1596–1604.
Karvonen HM, Lehtonen ST, Sormunen RT, Harju TH, Lappi-Blanco E, Bloigu RS, et al. Myofibroblasts in interstitial lung diseases show diverse electron microscopic and invasive features. Lab Invest 2012;92:1270–1284.
Sato C, Manaka S, Nakane D, Nishiyama H, Suga M, Nishizaka T, et al. Rapid imaging of mycoplasma in solution using atmospheric scanning electron microscopy (ASEM). Biochem Biophys Res Commun 2012;417:1213–1218.
Kannan TR, Musatovova O, Balasubramanian S, Cagle M, Jordan JL, Krunkosky TM, et al. Mycoplasma pneumoniae community acquired respiratory distress syndrome toxin expression reveals growth phase and infection-dependent regulation. Mol Microbiol 2010;76:1127–1141.
Zhang H, Shang YX, Zhou XN He MB, Jiao XY,W L, et al. Changes of lungs in BALB/c mouse after mycoplasma pneumonia infection in different periods. Anatomy Res (Chin) 2012;34:8–11.
Yan T. Role of anti-inflammatory cytokines in pathogenesis of pediatric mycoplasma pneumoniae pneumonia. J Biol Regul Homeost Agents 2016;30:541–545.
Du J, Han JC, Zhang YJ, Qi GB, Li HB, Zhang YJ, Cai S. Single-nucleotide polymorphisms of IL-17 gene are associated with asthma susceptibility in an Asian population. Med Sci Monit 2016;22:780–787.
Rathore JS, Wang Y. Protective role of Th17 cells in pulmonary infection. Vaccine 2016;34:1504–1514.
0
浏览量
0
Downloads
2
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 邮编：100091
- 联系电话：010-62886827, 62877592 传真：010-62874291
- 技术支持由北京北大方正电子有限公司提供 京ICP备05067934号-1
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
